, Tracking Stock Market Picks
Enter Symbol:
Aeterna Zentaris, Inc. (AEZS) [hlAlert]

down 99.40 %

Aeterna Zentaris, Inc. (AEZS) rated Buy with price target $5 by Needham

Posted on: Tuesday,  May 31, 2011  8:25 AM ET by Needham

Needham rated Buy Aeterna Zentaris, Inc. (NASDAQ: AEZS) on 05/31/2011, when the stock price was $15.00. Since
then, Aeterna Zentaris, Inc. has lost 99.40% as of 12/02/2015's recent price of $0.09.
If you would have followed this Needham's recommendation on AEZS, you would have lost 99.4% of your investment in 1646 days.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology. The product pipeline of the Company encompasses compounds at all stages of development, from drug discovery through marketed products. The Company’s principal product candidates include cetrorelix for benign prostatic hyperplasia (BPH) and AEZS-108 for endometrial and ovarian cancers. In January 2007, the Company completed the spin-off of Atrium Biotechnologies Inc., known as Atrium Innovations (Atrium). On November 30, 2007, the Company completed the sale of its Utah-based subsidiary, Echelon Biosciences Inc. (Echelon), to Frontier Scientific Inc.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/31/2011 8:25 AM Buy
15.00 30.00
as of 12/30/2011
1 Week down  -2.53 %
1 Month down  -3.75 %
3 Months up  1.31 %
1 YTD down  -38.40 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy